Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

The discovery that their neonatal diabetes is caused by gain-of-function mutations in the K(ATP) channel has enabled many patients to switch from insulin to oral sulphonylurea drugs. Here, I review molecular, physiological, and clinical features of this change in therapy.

Original publication

DOI

10.1016/j.cmet.2010.02.004

Type

Journal article

Journal

Cell Metab

Publication Date

03/03/2010

Volume

11

Pages

179 - 181

Keywords

Animals, Diabetes Mellitus, Diabetes Mellitus, Experimental, Humans, Infant, Newborn, Insulin, KATP Channels, Mice, Mutation, Sulfonylurea Compounds